Icon

Triumeq PD - (60mg/5mg/30mg; Tablet for Suspension)

Abacavir Sulfate, Dolutegravir and Lamivudine VIIV Healthcare
60mg/5mg/30mg; Tablet for Suspension
More Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
TRIUMEQ PD is a combination of dolutegravir (integrase strand transfer inhibitor [INSTI]), abacavir, and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) indicated for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 10 kg
Yes
Triumeq PD Patent 1 Patent 2
***** ******* **** *** *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ ********* -**- *** ********* ********* ******** ******* *** **** (***** ******) *** *** ****
  1. *** **, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** **, **** : ***** *** ********* ********. **, ** ****** **** ***** **** ***** **** *** **** ***** ****** '***.

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.